Investors largely shrugged off the most recent earnings report from United Therapeutics (NASDAQ: UTHR) , a pharma company that focuses on pulmonary hypertension. Sometimes, however, past financial results can cloud the vision a company has for its future. The savviest investors look to the past and to the future when deciding whether or not to make a purchase. I think that the growth potential United Therapeutics offers may prove to be be a breath of fresh air for shareholders.
While revenue for the company's leading product for pulmonary hypertension, Remodulin, was down 12% from fiscal 2019 to fiscal 2020 (from $587 million to $516.7 million) due to generic competition coming to market in 2018, another pulmonary hypertension treatment, Tyvaso, gained 16% in in that time, from $415.6 million to $483.3 million. Management is currently seeking expanded labeling for Tyvaso for pulmonary hypertension and interstitial lung disease, hoping to double the number of patients taking the drug within 18 months. A decision from the U.S. Food and Drug Administration (FDA) is due in April.
Image source: Getty Images.
For further details see:
This Pharma Can Breathe New Life Into Your Portfolio